# Amgen to acquire Oxford spinout Dark Blue, tucking in a preclinical cancer drug

**Source:** Endpoints News
**URL:** https://e.endpointsnews.com/t/t-l-wpiudl-jykykhhuld-d/
**Date:** 2026-01-07

---

Alastair MacKinnon, Dark Blue Therapeutics CEO

January 6, 2026 10:49 AM EST DealsR&D

Am­gen to ac­quire Ox­ford spin­out Dark Blue, tuck­ing in a pre­clin­i­cal can­cer drug

Andrew Dunn

Senior Biopharma Correspondent

Cal­i­for­nia bio­phar­ma gi­ant Am­gen is pay­ing as much as $840 mil­lion to boost its on­col­o­gy pipeline, agree­ing to ac­quire an Ox­ford Uni­ver­si­ty spin­out for its …

---

#news #endpoints-news
